RxDoctor Payments Data

Reena Shah, MD

Neurology · Cincinnati, OHNPI 1649305863

Payments from drug & device makers

$204,480in general payments, 2019–2025

Across 346 payments — averaging $590.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$117K
  • AbbVie$26K
  • H. Lundbeck A S$24K
  • Biohaven Pharmaceutical Holding Company Ltd.$20K
  • Lundbeck LLC$8K
  • Biohaven Pharmaceuticals, Inc.$7K
  • plus $2K from 6 others

What the payments were for

  • Consulting fees$10,4676%
  • Speaking & faculty fees$162,09490%
  • Grants$850%
  • Travel & lodging$3,8712%
  • Food & beverage$3,3402%
  • Education$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$204,480 in reported general payments places this provider in the 85th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$12,361
Medicare patients
60
Services billed
202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant85$108,193
QuliptaAtogepant57$73,775
Nurtec OdtRimegepant Sulfate40$54,016
Emgality PenGalcanezumab-Gnlm66$46,644
ReyvowLasmiditan Succinate58$46,616
ZavzpretZavegepant Hcl23$24,326
Ajovy AutoinjectorFremanezumab-Vfrm14$14,603
Aimovig AutoinjectorErenumab-Aooe15$13,201
Sumatriptan15$4,156
Sumatriptan Succinate80$2,954
Memantine Hcl52$2,759
Memantine Hcl ErMemantine Hcl25$1,722
Naratriptan Hcl46$1,634
Gabapentin80$1,020
Topiramate82$848

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$25,728$181,968142 claims
PfizerNurtec Odt, Zavzpret$1,525$78,34363 claims
Lilly USA, LLCReyvow$117,493$46,61658 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 702 neurology providers in Ohio.

Other neurology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →